Nosopharm is an innovative biotechnology company specialized in the research and development of new molecules to combat antimicrobial resistance (AMR).
Location: France, Auvergne-Rhône-Alpes, Lyon
Total raised: $5.73706M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | Auriga Par... | auriga.vc |
| 27.03.2021 | Elaia Part... | elaia.com |
Funding Rounds 3
| Date | Series | Amount | Investors | Deal News |
| 25.11.2020 | - | $1.905744M | Kreaxi | - |
| 12.02.2018 | - | $1.235383M | - | finsmes.co... |
| 28.03.2017 | - | $2.595933M | Kreaxi | finsmes.co... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 15.07.2022 | Former Sp... | Joseph La Barge → Dave Green... | - | Alex Hoffm... | endpts.com... |
| 12.02.2018 | Nosopharm ... | Nosopharm, a Lyon, France-base... | France | - | finsmes.co... |
| 29.03.2017 | Term Sheet... | IPOS ARE COOL AGAIN For that ... | - | - | fortune.co... |
| 28.03.2017 | Nosopharm ... | Nosopharm, a Lyon, France-base... | France | - | finsmes.co... |